Factor IX antihemophilic factor with increased clotting activity
    1.
    发明授权
    Factor IX antihemophilic factor with increased clotting activity 失效
    因子IX抗血友病因子具有增加的凝血活性

    公开(公告)号:US06531298B2

    公开(公告)日:2003-03-11

    申请号:US09118748

    申请日:1998-07-17

    CPC classification number: C12N9/644 A61K38/00 C12Y304/21022

    Abstract: A non-naturally occuring Factor IX protein having an amino acid substitution at amino acid position 338 is provided. Preferred substitutions include the substitution of analanine, leucine, or valine for the arginine at amino acid position 338. Factor IX of the present invention is non-naturally occuring (e.g., does not contain only an arginine to proline substitution at amino acid position 338). Factor IX proteins of the invention are useful for facilitating blood clotting in subjects in need thereof, such as subjects afflicted with hemophilia B. Pharmaceutical formulations comprising Factor IX of the invention are provided, along with nucleic acids encoding the factor and vectors containing such nucleic acids.

    Abstract translation: 提供了在氨基酸位置338具有氨基酸取代的非天然存在的因子IX蛋白质。 优选的取代包括在氨基酸位置338将精氨酸替换为鸟嘌呤,亮氨酸或缬氨酸。本发明的因子IX是非天然存在的(例如,在氨基酸位置338处不含有精氨酸至脯氨酸取代) 。 本发明的因子IX蛋白质可用于促进有需要的受试者例如患有血友病B的受试者的血液凝固。提供包含本发明的因子IX的药物制剂以及编码所述因子的核酸和含有该核酸的载体 。

Patent Agency Ranking